Philippe Menu Sells Shares of SOPHiA GENETICS
Chief Medical Officer Philippe Menu sold 5,000 shares at $4.95 each, totaling $24,750.
Key Points
- Philippe Menu, the Chief Medical Officer at SOPHiA GENETICS, sold 5,000 shares on June 12, 2026, for $24,750.
- SOPHiA GENETICS, trading at $4.88, has a market cap of $359.7 million and a 52-week range of $2.59 to $5.70.
- BTIG reiterated a buy rating with an $8.00 target, while other insiders also made recent trades.
Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, sold 5,000 shares of the company on June 12, 2026. The shares were sold at an average price of $4.95, amounting to a total transaction value of $24,750. This sale was part of a planned transaction.
Insider Buying and Selling at SOPHiA GENETICS SA
In addition to Philippe Menu's transaction, other recent insider activities include CEO Jurgi Camblong selling 8,500 shares at $5.24 each on June 10, 2026, under a planned sale. On June 5, 2026, CFO George Cardoza bought 20,000 shares at $4.95 each. Philippe Menu also sold shares on May 26, 2026, and May 19, 2026, at $4.95 and $4.61 respectively, both of which were planned sales.
Other Institutional Activity in SOPHiA GENETICS
Several institutional investors have also shown interest in SOPHiA GENETICS. Royce & Associates LP significantly increased its holdings by 1,386,055 shares, bringing its total to 1,816,312 shares worth approximately $8.99 million. Soleus Capital Management, L.P. added 1,850,000 shares, ending with 1,850,000 shares valued at $9.16 million. Meanwhile, Principal Financial Group Inc made a smaller addition of 9,800 shares, bringing its total to 1,409,242 shares valued at around $6.98 million.
SOPHiA GENETICS Stock Snapshot
Shares of NasdaqGS:SOPH traded near $4.88. SOPHiA GENETICS has a market capitalization of approximately $359.7 million. The company currently does not have a meaningful P/E ratio due to its lack of profitability, but it has a forward P/E of -8.95. The stock's 52-week range is between $2.59 and $5.70, with a 50-day moving average of $4.99 and a 200-day moving average of $4.64. The company's balance sheet shows a current ratio of 2.06 and a quick ratio of 1.71, with a debt-to-equity ratio of 136.63.
Recent Earnings
SOPHiA GENETICS reported revenue of $81.18 million with a growth rate of 22%. The company is not currently profitable, with a net margin of -99.7% and a return on equity of -123.3%. The next earnings report is expected on August 4, 2026.
Analysts Set New Price Targets
On June 15, 2026, BTIG reiterated its buy rating for SOPHiA GENETICS with a price target of $8.00. The consensus among analysts is a buy recommendation, with an average price target of $8.00 based on three analyst opinions.
About SOPHiA GENETICS
SOPHiA GENETICS SA is a healthcare technology company based in Rolle, Switzerland. It specializes in cloud-native software for analyzing and interpreting complex medical data. The company's flagship platform, SOPHiA DDM, helps hospitals, laboratories, and biopharmaceutical companies analyze multi-modal data sets. SOPHiA GENETICS was founded in 2011 and is led by CEO Dr. Jurgi Camblong. It operates internationally, with a significant presence in Europe, North America, and the Asia-Pacific region.
Bottom Line
Philippe Menu's recent sale is part of a planned transaction and reflects ongoing insider activity at SOPHiA GENETICS. The company, while not currently profitable, continues to attract institutional investor interest. Analysts maintain a positive outlook with a buy rating and price targets suggesting potential upside. As always, it's important to remember that insider and institutional transactions provide insight but are not direct indicators of future stock performance.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.